Amalgamated Financial’s Bionano Genomics BNGO Stock Holding History

Amalgamated Financial’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$123K	Buy	+79	New	+$107K	﹤0.01%	2072

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Amalgamated Financial's BNGO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Bionano Genomics (BNGO) in Q1 2022: 79 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #2072 among its holdings.

148 funds tracked by Wall St. Rank hold BNGO as of Q1 2022.

Amalgamated Financial held 79 shares of Bionano Genomics worth $123K as of Q1 2022.
Bionano Genomics was a new Amalgamated Financial position in Q1 2022.
Bionano Genomics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2072 holding.
148 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.